Imidamide Sphingosine Kinase Inhibitors Substrate Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inhibiting sphingosine kinases lack selectivity and potency, particularly in targeting the substrate-binding domain of SphK1 and SphK2, which are crucial for therapeutic applications such as cancer treatment and vascular health, due to the conserved ATP binding site across kinases and limited oral bioavailability of existing compounds.
Innovation Solution
Development of novel compounds, specifically those of Formula IA, which inhibit sphingosine kinase 1 and 2 enzymes with enhanced selectivity and potency by targeting the substrate-binding domain, and their use in pharmaceutical compositions for treating neoplastic diseases, vascular injuries, and other conditions, including angiogenesis inhibition and asthma management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional ATP binding site inhibition strategy is used, then sphingosine kinase inhibition is achieved, but selectivity across kinases is limited
Solution Approach 1:
The patent extracts the inhibition function from the conserved ATP binding site to the unique substrate-binding domain of sphingosine kinases. By designing compounds that specifically target the substrate-binding pocket rather than the common ATP site, the invention achieves selective inhibition of SphK1 and SphK2 while sparing other kinases in the DAG kinase family.
Solution Approach 2:
The invention applies local quality by creating inhibitors that interact with specific local features of the substrate-binding domain. The compounds are designed to exploit unique structural characteristics of the sphingosine binding pocket, such as specific amino acid residues and spatial arrangements, rather than targeting the general kinase ATP binding region.
2Reliability
If existing sphingosine kinase inhibitors are used, then enzyme inhibition is achieved, but oral bioavailability is poor
Solution Approach 1:
The patent applies parameter changes by systematically modifying the physicochemical properties of the inhibitor molecules. The compounds are designed with optimized molecular weight, lipophilicity, hydrogen bonding capacity, and other parameters to enhance oral absorption while maintaining potent enzyme inhibition. This involves balancing hydrophobic and hydrophilic regions to achieve appropriate membrane permeability and solubility.
3Reliability
If ATP binding site targeting is used, then sphingosine kinase inhibition is achieved, but the conserved sequence across DAG kinase family members causes cross-reactivity
Solution Approach 1:
The patent extracts the inhibition function from the conserved ATP binding site to the unique substrate-binding domain of sphingosine kinases. By designing compounds that specifically target the substrate-binding pocket rather than the common ATP site, the invention achieves selective inhibition of SphK1 and SphK2 while sparing other kinases in the DAG kinase family.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit SphK enzymes, offering improved selectivity and oral bioavailability, thereby providing therapeutic benefits in treating various diseases like cancer, vascular issues, and asthma by modulating sphingosine-1-phosphate levels, thereby addressing the limitations of existing inhibitors.
Implementation Method 1
compounds that inhibit sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) enzymes
Data Source
AI summary
Imidamide (amidine) analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumors.